Chronic Myeloid Leukemia (CML)

What is Adult Chronic Myeloid Leukemia?

Adult Chronic myeloid or myelogenous leukemia (CML) is a type of cancer in which the bone marrow makes too many white blood cells. Although rare compared to other types of cancer such as colon, lung, prostate, or breast cancer, adult CML is diagnosed in fewer than 5,000 people each year in the United States. Most cases occur in adults, and risk increases with age. The physicians at Rocky Mountain Cancer Center (RMCC) and the Rocky Mountain Blood and Marrow Transplant Program (RMBMTP) are specialists in the care of patients with CML.

CML may be called by several names, including chronic granulocytic, chronic myelocytic, or chronic myelogenous leukemia.

CML is a disease in which too many immature white blood cells (blasts) are produced in the bone marrow. The uncontrolled growth and accumulation of these immature cells builds up, preventing the production of normal blood cells leading to a deficiency of red blood cells, blood-clotting platelets, and normal infection-fighting white blood cells. When this happens, infection, anemia, or easy bleeding may occur.

What causes CML?

CML is distinguished from other types of leukemia by the presence of a genetic abnormality in blood cells called the Philadelphia chromosome (so named because the discovery was made at the University of Pennsylvania School of Medicine in Philadelphia). The cause of CML is unknown. In a small number of patients, the cause is exposure to very high doses of radiation (most carefully studied in the Japanese survivors of the atomic bomb). A slight increase in risk also occurs in some people treated with high-dose radiation therapy for other cancers.

How is CML diagnosed?

Possible signs of adult CML, which usually develop gradually, include tiring easily and shortness of breath when physically active. Most patients feel a loss of well-being or have a pale complexion from anemia. Discomfort on the left side of the abdomen from an enlarged spleen is frequently seen in patients with CML. Patients may also experience excessive sweating, night sweats, fever, weight loss, and intolerance for warm temperatures. The disease is often discovered during a “routine” physical examination.

Doctors use tests that examine the blood and bone marrow to detect and diagnose adult CML, including:

  • Physical examination and history

  • Complete blood count

  •      
  • Number of red blood cells, white blood cells, and platelets

  •      
  • Amount of hemoglobin (protein that carries oxygen) in the red blood cells

  •      
  • Portion of the sample made up of red blood cells

  • Bone marrow aspiration and biopsy (looking for abnormal cells)

  • Cytogenetic analysis to analyze the number and shape of the chromosomes of cells

  • Polymerase chain reaction (PCR) or FISH testing to detect chromosome breakage


Blood and bone marrow cells usually reveal very high levels of white cells. Examination of the stained (dyed) blood cells under a light microscope shows a small proportion of immature cells (leukemic blast cells) and a larger proportion of maturing and fully matured white cells (myelocytes and neutrophils). A sample of marrow is examined to confirm the blood findings and to determine if there is an abnormality in the chromosomes. The presence of the Philadelphia chromosome (a shortened chromosome number 22) in the marrow cells, high white blood cell counts, and other characteristic blood and marrow findings confirm the diagnosis of CML.

After CML has been diagnosed, further tests determine the phase of the cancer. A doctor might use the following procedures to find out the phase: cytogenetic analysis (looking for changes in chromosomes in the blood) or bone marrow aspiration and biopsy.

There is no standard staging system for CML—it is classified by phase instead: chronic phase, accelerated phase, or blastic phase. The plan of treatment is determined by the phase.

As the amount of blast cells increases in the blood and bone marrow, there is less room for healthy blood cells. The amount of blast cells in the blood and bone marrow and the severity of symptoms (infections, anemia, easy bleeding, bone pain, and pain below the ribs on the left side) determine the phase of the disease.

  • Chronic phase – in the chronic phase of CML, 5% or fewer of the cells in the blood and bone marrow are blast cells.

  • Accelerated phase – in the accelerated phase of CML, 6% to 20% of the cells in the blood and bone marrow are blast cells.

  • Blastic phase – in the blastic phase of CML, more than 20% of the cells in the blood and bone marrow are blast cells.


What are the treatment options?

Most patients are initially treated with Imatinib or Gleevec, a pill from a class of drugs known as tyrosine kinase inhibitors. It is a very effective treatment although we do not yet know if it can cure the disease. The only known cure is allogeneic transplant, which can cure 60-80% of patients in the chronic phase, but is quite risky as well. It is very important to discuss the possibility of stem cell transplantation for almost all patients who have CML.

Chronic Phase CML Treatments:

  • Allogeneic stem cell transplantation


Accelerated Phase CML Treatments:

  • Allogeneic stem cell transplantation

  • Other drug therapy (Gleevec)

  • Experimental therapy


Blastic Phase CML Treatments:

  • Experimental therapy

  • Increase Gleevec doses

  • Allogeneic stem cell transplantation

  • Chemotherapy or palliative therapy to relieve symptoms and improve quality of life


In 1998 a study conducted by the Fred Hutchinson Cancer Research Center showed that CML patients who received a bone marrow transplant from a tissue-type matched unrelated donor could expect about the same five-year survival rate as patients with matched related donors.



Related Patients & Caregivers Links: THE BASICS, PLANNING FOR TRANSPLANT, THE POST-TRANSPLANT PROCESS, THE PRE-TRANSPLANT PROCESS, THE TRANSPLANT PROCESS
Related News: Ceflatonin receives U.S. FDA orphan drug designation for treatment of chronic myeloid leukemia, Researchers Seek Alternative For Leukemia Patients Resistant To Standard Therapies, Preclinical research supports Ceflatonin in treatment of acute myeloid leukemia, Chronic myeloid leukemia response to imatinib predicted by quantitation of BCR-ABL transcript, Cytogenetic response to prior IFN treatment predicts survival after AHSCT in CML, Leukemia patients experienced molecular remission after imatinib treatment, Leukemia patients receiving imatinib should be advised to practice adequate contraception, Researchers from Italy, the United States and Japan report details of new studies and findings in the area of leukemia, Triple purge strategy eliminates chronic myelogenous leukemia cells from autografts, Findings from Italy and Japan in leukemia provide new insights, Quest Diagnostics launches tests to assess status of leukemia and lymphoma in using blood plasma, SGX Pharmaceuticals and Novartis collaborate on BCR-ABL inhibitors for chronic myelogenous leukemia, An Interactive Dialog on Myeloma, Lymphoma and Leukemia: Clinical Integration of Recent Advances was held in Scottsdale on May 20, 2006, FDA Okays Sprycel for CML Resistant or Intolerant to Gleevec, Drug that battles resistance to leukemia pill Gleevec shown to be effective against cancer, ChemGenex launches multinational phase 2/3 study for CML patients with T315I mutation, Chronic myelogenous leukemia patients exhibit altered bone and mineral metabolism while receiving imatinib, Unrelated cord blood transplantation is an alternative for adults with hematological malignancies lacking an HLA-matched donor, Investigators review the antigen-specific cellular immunotherapy of leukemia in a recent issue of the journal Leukemia, Patients with treatment-resistant leukemia achieve high responses to Tasigna (nilotinib) in first published clinical trial results, University of California researchers report new molecule that targets leukemia and lymphoma cells, ChemGenex presents data on Ceflatonin for treating CML patients resistant to Gleevec, Imatinib mesylate treats secondary malignancy with favorable outcome, Investigators review the antigen-specific cellular immunotherapy of leukemia in a recent issue of the journal Leukemia, A new chronic myeloid leukemia (CML) staging system was proposed, Chronic myeloid leukemia (CML) patients might experience molecular remission after imatinib mesylate treatment, 3-substituted benzamide derivatives could be used to treat chronic myeloid leukemia (CML), Unrelated cord blood transplantation feasible in adults with high-risk malignancy, U.S. FDA approves Sprycel (dasatinib) with two indications, ChemGenex teams with MolecularMD to identify CML patients with T315I drug resistance mutation, Leukemia developed in patient with primary thrombocythemia and absence of BCR/ABL rearrangement, Gene expression molecular signature identified in chronic myeloid leukemia, Dasatinib studied in patients with leukemia and resistance or intolerance to imatinib, Antigen identified as possible immunotherapy for myeloid leukemias, U.S. FDA gives rapid approval for new treatment for chronic myeloid leukemia, BCR-ABL transcript level patterns after allograft is variable in chronic myeloid leukemia, Scientists isolate leukemia causing stem cells in a mouse model of human leukemia, BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia, FHIT gene therapy using chimeric adenovirus shows promise for leukemia, Philadelphia chromosome-positive leukemia treated with dasatinib, Dasatinib targets earlier progenitors than imatinib in primary chronic myeloid leukemia, Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners studied, Targets of aberrant hypermethylation identified in myeloid leukemia, Cases of chronic myelogenous leukemia and rheumatic disease linked, Leukemia response to dasatinib evaluated
 
RECENT NEWS
 
New drug combination brings 1-2 punch against acute leukemia Researchers at The University of Texas M. D. Anderson Cancer Center have discovered a drug combination that kills leukemia cells by shutting down their energy source and hastening cell starvation. More...
Mile High Amazing Race Downtown Denver 5/17 Get ready for the most AMAZING RACE for Life! Many have seen the television show; now here's a chance to race in your own adventure! The 2nd Annual Mile High Amazing race to Benefit The Leukemia, Lymphoma's Society is a one-day event that will be on Saturday, May 17, 2007 in Downtown Denver. More...
Stem Cell Transplant Procedures Vary Throughout the World Stem cell transplant practices vary substantially among physicians treating adults and children with hematologic malignancies (cancers of the blood or bone marrow such as leukemias and lymphomas). These findings were published in the Journal of Clinical Oncology. More...
Arsenic-based therapy shown to help eradicate leukemia-initiating cells In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence. More...
Lenalidomide raises clot risk in multiple myeloma patients Thromboembolic events are increased in patients undergoing lenalidomide-based therapy for multiple myeloma, US and Italian researchers report. Aspirin prophylaxis appears to reduce this risk. More...
 
UPCOMING EVENTS
 
Young Adult Support Group If you are between the ages of 17 and 27 and are coping with cancer or a blood disorder, please join us. More...
Leukemia and Lymphoma Society Family Support Groups Looking for support aournd a diagnosis of Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Myeloma? The Leukemia and Lymphoma Society offers support groups for patients, family members, friends, a. More...
Family Member and Caregiver Support Group A weekly group for family members and caregivers of BMT patients to give and receive support, ask questions, swap ideas, be heard, listen and take a break. More...
BMT Reunion Pictures Attention BMT Reunion Participants Please click on the link below to view the pictures from the BMT Patient/Caregiver Reunion that was held on Saturday, October 13th, 2007. More...
 
RECENT CLINICAL TRIALS
 
Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants More...
02057 - A Randomized Trial of Neulasta (Pegfilgrastim) Versus Neupogen (Filgrastim) to Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma More...
Treatment of Relapsed or Primary Refractory Hodgkin Lymphoma with High-Dose CBV Followed by Autologous Peripheral Blood Progenitor Cell Rescue More...
Urine Characteristics of Chronic Renal Dysfunction Following Myeloablative and Non-Myeloablative Hematopoietic Cell Transplantation More...
1581 - Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with STI-571 Responsive Ph+ Acute Leukemia - Multi-Center Trial More...
 
RECENT PATIENT STORIES
 
Bob Heykoop "People caring about one another represents life's greatest value." – Jim Rohn More...
George Poynter George Poynter would not be here today without the Rocky Mountain Blood and Marrow Transplant Program and its medical director, Dr. Jeff Matous. More...
Maggie Brunner In the weeks leading up to her transplant, Maggie Brunner and her husband had to ask each other some difficult questions. More...
Leslie Szabo What surprised Leslie most after her transplant was how long it took her to get back to what could be considered a relatively normal life. More...
Janice Gangl Not knowing what was wrong with me for so long was really terrifying. More...